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PRIMARY CARE PHYSICIAN DELIVERED BRIEF BEHAVIORAL INTERVENTION FOR
ADULT OBESITY AND ASSOCIATED HEALTH CONDITIONS

Julia C. Huston, Ph.D.
Western Michigan University, 2018

Obesity is a chronic health condition with prevalence rates that have continued to rise
steadily over the past 30 years to the point that it has now been declared a global epidemic and a
serious public health concern. Obesity is associated with significant physical and economic costs,
primarily resulting from co-occurring health conditions that increase the risk of morbidity
including type II diabetes, hypertension, dyslipidemia, stroke, coronary heart disease, and
respiratory problems. Despite the dissemination of several obesity treatments, including
pharmacotherapy, lifestyle modification, and bariatric surgery, the prevalence and severity of
obesity continues to rise. Federal guidelines recommend the use of lifestyle interventions
involving behavioral strategies to reduce caloric intake and increase physical activity, yet there is
limited research examining the effectiveness and feasibility of delivering these interventions in
community settings, particularly within primary care medical offices. Primary care providers
(PCPs) play a critical role in diagnosing, monitoring, and treating obesity and co-morbid health
conditions, yet there are many barriers to implementing lifestyle interventions in primary care
including time, resource, and knowledge constraints.
The current study evaluates the effectiveness and feasibility of a brief behavioral
intervention for obesity delivered by PCPs in an outpatient internal medicine office. Physician

training and regular electronic between visit check-ins are utilized to address commonly cited
barriers to the delivery of lifestyle interventions in primary care. Outcome variables included
weight and BMI as well as severity measures of common obesity-related health conditions
including sleep quality, depression, diabetes, hypertension, and hyperlipidemia.
Participants (N = 31) received either brief behavioral intervention (n = 15) or usual care
(n = 17) for obesity, depending on their pre-existing PCP, over a 12-month period. Linear mixed
modeling analysis revealed a statistically significant difference in rates of change for hemoglobin
A1c over time between participants in the behavioral intervention and usual care conditions.
Specifically, A1c values decreased for those in the intervention group and increased for those in
the usual care group. No other statistically significant results were found and data trends revealed
mixed results for the remaining outcome variables. Consumer satisfaction data for the behavioral
intervention revealed high feasibility and usefulness ratings from PCPs and patients.
These findings reveal that the brief behavioral intervention, though viewed as valuable
and feasible by both PCPs and patients, resulted in statistically significant improvement in only
one obesity associated health condition over time relative to usual care. The current study is
limited by a small sample size and inconsistent data collection across participants and time
points, however, these results have implications for the development of a population-based tiered
model of care for obesity. It is possible that the brief behavioral intervention used in the current
study could be a first level intervention that might be particularly effective for specific subpopulations, whereas others may need additional levels of intervention. Future research should
continue investigating effective implementation of behavioral interventions for obesity in
community settings including primary care.
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INTRODUCTION
Scope and Significance of the Problem
Obesity can be defined as abnormal or excessive fat accumulation in the body’s adipose
tissue (WHO, 2000). Body mass index (BMI) is an easily obtained and commonly used
screening measure for obesity, though it does not measure body fat directly. BMI is calculated as
the ratio of a person’s weight (kg) to the square root of their height (m) and has been shown to be
correlated with measures of body fat and adverse health outcomes (Flegal & Graubard, 2009;
National Institutes of Health, 1998). When a person’s weight is higher than what is considered to
be healthy for their height, they are considered to be overweight or obese. Within this
categorization, there are varying levels of severity: overweight is defined as having a BMI
between 25 and 29.9, class 1 obesity entails having a BMI between 30 to 34.9, class 2 obesity
involves a BMI between 35 and 39.9, and class 3 (severe) obesity is identified by a BMI greater
than or equal to 40 (National Institutes of Health, 1998; WHO, 2000).
Obesity is a chronic health condition that is increasing in prevalence around the world. In
2012, there were over 78 million obese adults in the United States alone (Ogden, Carroll, Kit, &
Flegal, 2014). The age-adjusted percentage of U.S. adults with obesity has increased from 22.9%
to 37.89% between 1988 and 2014 (U.S. Department of Health and Human Services, 2017).
These steadily rising rates over the past 20 years have resulted in obesity being declared a global
epidemic and a serious public health concern. In 2000, poor diet and physical inactivity together
accounted for the second highest number of deaths in the United States; 400,000 deaths, making
up 16.6% of total U.S. deaths (Mokdad, Marks, Stroup, & Gerberding, 2004).
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Obesity is also associated with many other health conditions that increase an individual’s
risk of morbidity including: hypertension, dyslipidemia, type II diabetes mellitus, stroke,
coronary heart disease, gallbladder disease, sleep apnea, respiratory problems, osteoarthritis, and
some types of cancer (e.g., liver, kidney, endometrial, breast, prostate, and colon; Aronne, 2001;
Must et al., 1999; National Institutes of Health, 1998; U.S. Department of Health and Human
Services, 2013). In 2015, heart disease, cancer, stroke, and diabetes were all listed within the top
10 leading causes of death in the United States (U.S. Department of Health and Human Services,
2017). Additionally, obese individuals experience psychosocial problems including
stigmatization, discrimination, and reduced quality of life, which increases risk for premature
mortality (National Institutes of Health, 1998; WHO, 2000).
A cohort study conducted in Washington on 73,003 adults, aged 50 to 76 years, examined
the relationship between BMI and over 40 other health conditions. The results revealed that 90%
and 71% of the conditions examined were associated with increased BMI in females and males,
respectively (Patterson, Frank, Kristal, & White, 2004). Of particular concern is the fact that
among the subcategories of obesity, the prevalence of severe obesity is increasing at the highest
rate in the U.S. population. This is especially concerning because the most severe health
conditions that tend to be comorbid with obesity are most likely to occur in individuals who are
severely obese (Arterburn & Courcoulas, 2014; Sturm, 2007; U.S. Department of Health and
Human Services, 2017). Additionally, increased mortality has been found to be particularly
associated with higher levels of obesity, relative to normal weight categories (Flegal, Graubard,
Williamson, & Mitchell, 2005).
There are significant economic costs associated with the many medical consequences of
obesity. Finkelstein, Trogdon, Cohen, and Dietz (2009) report that rising rates of obesity have
2

been linked to increases in medical spending. In 1995, the total cost attributable to obesity and
associated health conditions was $99.2 billion, with more than half resulting from direct medical
costs which comprised 5.7% of the national health expenditure (Wolf & Colditz, 1998).
Additionally, in 1994 there were 39.2 million lost work days, 239 million restricted activity days,
89.5 million bed days, and 62.6 million physician visits attributable to obesity, resulting in an
extra $3.9 billion in lost productivity costs. In comparison to 1988 data, by 1994 lost work days
increased by 50%, restricted activity days increased by 36%, bed days increased by 28%,
physician visits increased by 88%, all attributable to obesity (Wolf & Colditz, 1998). There is no
reason to assume that the economic impact of obesity has slowed or reversed in recent years.
As of 2009, the annual medical burden of obesity accounted for almost 10% of all
medical spending. Across all payers in 2006, the per capita medical spending for obese
individuals was 42% greater than the per capital medical spending of non-obese individuals. On
average, each obese beneficiary cost Medicare $600 more per year than each non-obese
beneficiary. This economic burden to public and private payers results almost entirely from the
treatment of the many health conditions associated with obesity (Finkelstein, Trogdon, Cohen, &
Dietz, 2009). The pharmacotherapy costs for obesity attributable diseases constitute a much
larger percentage of total treatment costs than for other diseases and non-obese patients. The
greatest costs among obese patients are for drugs to treat comorbid conditions including
hypertension, diabetes, and cardiovascular diseases, as well as antidepressants and respiratory
and ulcer medications (Aronne, 2001).
Obesity Treatment
A nationally representative sample revealed that 64.3% of U.S. adults have a desire to
lose weight, however, only 48.4% reported pursuing some form of weight control (Yaemsiri,
3

Slining, & Agarwal, 2011). Treatment guidelines recommend medically-directed weight loss for
individuals who are obese (BMI ≥ 30) and those who are overweight (BMI between 25-30) if
comorbid health conditions are also present (Ryan, 2016). Weight loss among obese individuals
is known to be associated with decreased incidence of obesity related health conditions and death
(Moyer, 2012). The majority of individuals with obesity report health improvement as a primary
motivator for weight loss (Doyle et al., 2012).
Despite continued increases in prevalence and the many physical, psychological, and
economic costs of obesity and associated health conditions, few evidence-based treatments exist
to target the growing obesity epidemic, and there is little agreement on the best treatment
approach (Arterburn, & Courcoulas, 2014). The limited success of treatments thus far is likely
due in part to the fact that obesity is a complex problem with a multifactorial etiology that
involves the interaction of both genetic and environmental factors, including culture (Comuzzie
& Allison, 1998; Hill & Peters, 1998; National Institutes of Health, 1998; WHO, 2000).
The genetic component of obesity involves predispositions mediated by many different
molecules involved in the regulation of food intake, energy expenditure, and fat storage
(Comuzzie & Allison, 1998; WHO, 2000). Contributing environmental factors include sedentary
lifestyle, energy dense food intake, and cultural factors that support an obese lifestyle. The
evolutionary drive to consume energy dense foods is no longer adaptive in the current
environment of abundance, yet modern society does not readily support the negative energy
balance needed to produce weight loss (Hill & Peters, 1998; WHO, 2000).
Although relatively little progress has been made with respect to successfully treating
obesity, there are several treatment modalities that have demonstrated effectiveness. These
include: bariatric surgery, pharmacotherapy, and lifestyle modification (Arterburn & Courcoulas,
4

2014). A comprehensive approach to treatment involving components of several different
therapeutic techniques is likely to produce the best results (Wadden et al., 2005). Most major
guidelines for obesity management suggest that comprehensive lifestyle intervention should be
the core treatment modality with other adjunctive treatments added for individuals who are at
higher risk and those who have failed to benefit from previous lifestyle interventions (Ryan,
2016). Unfortunately, both short and long-term success rates are still relatively low, and research
reveals that patients often have unrealistic expectations and prefer treatments that do not require
them to make substantial lifestyle changes (Doyle, 2012).
A review conducted by Aronne in 2001 suggested the following guidelines for utilizing
various weight loss treatment options: diet, exercise, behavioral therapy, and pharmacotherapy
are appropriate for obese individuals and those with a BMI less than 30 if comorbid health
conditions are also present. However, surgical interventions should be reserved for those patients
falling in the highest BMI categories who also have associated health complications. Current
U.S. guidelines recommend the consideration of bariatric surgery procedures for individuals who
have not responded to non-surgical treatments and who also have BMI of at least 40, or at least
35 if they are also suffering from serious comorbid health conditions (Arterburn & Courcoulas,
2014; Ryan, 2016). The U.S. Preventive Services Task Force recommends multicomponent,
intensive behavioral intervention for individuals with a BMI of 30 or higher (Moyer, 2012).
Currently, bariatric surgery is the treatment with the most definitive research support for
both significant and sustained weight loss and remission of obesity associated health conditions,
including type II diabetes (Arterburn, & Courcoulas, 2014; WHO, 2000). Refinements in the
efficacy and safety of bariatric surgery procedures have led to a twenty-fold increase in the
number of procedures performed annually in the U.S. over the past two decades (Arterburn &
5

Courcoulas, 2014). There are several risks associated with bariatric surgery procedures, though
the risks have decreased as the techniques have been refined. Reported incidence of short-term
post-surgery complications ranges from 4-25%, depending on a variety of patient and procedural
factors, but the overall risk of perioperative mortality is relatively low (0.3%). Reoperation as a
result of insufficient weight loss or complications occurs in some cases. There is also evidence
for increased long-term risk of suicide, nutritional deficiencies, and substance use disorders,
possibly due to changes in the way alcohol is absorbed by the body following bariatric surgery
(Arterburn & Courcoulas, 2014). Although bariatric surgery is beneficial for some individuals
with obesity, it is expensive and inappropriate for most individuals and, therefore, should not be
a first line treatment. There are risks and major lifestyle changes involved, including
modifications to the frequency, quantity, and content of food intake, as well as efforts to increase
energy expenditure through exercise, that should be carefully considered.
Pharmacotherapy is another available intervention option. There have been many
different weight loss medications introduced over the past 30 years for both short and long-term
obesity treatment, though some have since been withdrawn from the market due to safety
concerns. In general, obesity medications seek to promote weight loss through some combination
of the following mechanisms: increasing energy wastage, increasing energy expenditure, or
decreasing food intake. Many medications introduced solely to increase energy wastage or
expenditure have proved to be ineffective and are often associated with significant side effects
including malabsorption and a compensatory rise in food intake (Wilding, 2018). Many newer
weight loss medications seek to increase satiety and reduce food intake. There are currently a
handful of medications approved for either short-term (≤ 12 weeks) or long-term (≥ 12 weeks)
use in obesity management, though significant side effects, limited effectiveness, high out-of6

pocket costs, and lack of prescription guidance for providers remain barriers to widespread use
(Yanovski & Yanovski, 2014).
An analysis of prescription antiobesity medication use conducted by Hampp, Kang, and
Borders-Hemphill (2013) revealed that use of antiobesity drugs peaked in 1996, then sharply
declined, and over the past 10 years has begun to slowly increase again. The most common users
of antiobesity medications are women between 17 and 44 years of age. Phentermine, a
noradrenergic agent approved by the FDA for short-term use, was the most commonly prescribed
weight loss medication in the U.S. from 1991 through 2011. In addition to medications
introduced specifically for weight loss, there is some evidence supporting the use of medications
approved for the management of other conditions, such as diabetes (i.e. metformin, liraglutide,
pramlintide), epilepsy (i.e. zonisamide), and mood disorders (i.e. fluoxetine, bupropion), in the
treatment of obesity (Appolinario, Bueno, & Coutinho, 2004; Wilding, 2018; Yanovski &
Yanovski, 2014). Most medications have been found to produce maximum weight loss, as well
as additional improvements in obesity associated health conditions, when used in combination
with lifestyle modification (Ryan, 2016; Yanovski & Yanovski, 2014).
The final intervention modality with demonstrated effectiveness in treating obesity is
lifestyle modification. Comprehensive lifestyle interventions are those that include three main
components: a moderately reduced-calorie diet, increased physical activity, and the use of
behavioral strategies, including self-monitoring, goal setting and reinforcement, to facilitate
adherence to diet and exercise recommendations. These interventions can be delivered in low (≤
5 visits in 6 months), moderate (6-13 visits in 6 months), or high (≥ 14 visits in 6 months)
intensity formats (Ryan, 2016; U.S. Department of Health and Human Services, 2013). While
pharmacological and surgical interventions produce weight loss by modifying internal bodily
7

cues and systems that regulate appetite and satiety, lifestyle interventions produce weight loss by
teaching skills for managing the external environment as it relates to food consumption and
energy expenditure. Lifestyle modification is widely applicable and can be individually tailored
and delivered by a variety of professionals in many different formats and settings. Additionally,
behavioral interventions have shown demonstrated benefit and typically involve minimal risk
(Moyer, 2012).
Federal guidelines for managing overweight and obesity in adults reveal that, in
comparison to usual care involving limited provision of advice or educational materials,
comprehensive lifestyle interventions have demonstrated greater short, intermediate, and longterm weight loss. Additionally, electronically delivered comprehensive lifestyle interventions,
including both self-monitoring and individualized feedback from a trained professional, have
been shown to produce greater weight loss than the use of no intervention or knowledge gained
from widely available print or electronic materials (U.S. Department of Health and Human
Services, 2013). Intensive, multicomponent behavioral interventions have been shown to
produce not only weight loss among obese adults, but also improvement in glucose tolerance and
other cardiovascular risk factors (Moyer, 2012; Ryan, 2016). Additionally, there is evidence that
40-60% of overweight and obese adults maintain weight loss of at least 5% of initial body weight
two or more years after participating in a high-intensity, long-term, comprehensive lifestyle
intervention (U.S. Department of Health and Human Services, 2013).
Treating Obesity in Primary Care
Obesity and its associated health conditions often present first in primary care and are
typically managed by primary care physicians. In 2012, there were 11 million physician office
visits for obesity by adults age 20 and over. The majority of these visits (73%) included an
8

additional chronic condition, the most common of which were: hypertension, hyperlipidemia,
diabetes, and depression. Health education was offered at less than half of these visits (Talwalkar
& McCarty, 2016). Therefore, there is both an opportunity and a need for the provision of
information regarding the effects of excess weight on health and the delivery of lifestyle
interventions in primary care settings. One main advantage to providing interventions in primary
care is the fact that primary care physicians (PCPs) have contact with diverse segments of the
population and their advice is generally highly respected by patients. However, many PCPs are
uncomfortable providing behavioral recommendations and creating weight loss plans with
patients for a variety of reasons.
A study examining the attitudes and practices of over 1,000 physicians revealed that
while 75% of the physicians sampled reported that dietary counseling is a high priority for them,
65% reported that they spend five minutes or less discussing dietary concerns with their patients.
Additionally, more than two-thirds of the physicians sampled reported that less than 40% of the
patients seen in their practice actually receive nutritional counselling from their physician. Lack
of time was the most commonly cited barrier, followed by lack of patient compliance, inadequate
teaching materials, lack of knowledge and training in nutritional counseling, lack of adequate
reimbursement, and lack of confidence in ability to improve patient diet (Kushner, 1995).
Another more recent study (Smith et al., 2011) examined the practices of over 1,200
physicians and found that the practice of discussing energy balance in clinical care remains low
among primary care physicians. Less than half of the PCPs sampled reported calculating BMI for
their patients. The majority of PCPs reported providing some counseling to patients but less than
half reported always providing specific guidance, even to patients with weight related chronic
health conditions. Additionally, few PCPs reported consistently referring patients for further
9

management or systematically tracking patient behavior over time. In contrast to the low number
of physicians providing lifestyle counselling to their patients, almost 75% of PCPs reported
prescribing pharmacological treatments for weight control and almost 90% reported having
referred patients for bariatric surgery. The physicians sampled reported being more likely to
guide patients on exercise or diet specifically and less likely to provide guidance on overall
weight control (Smith et al., 2011).
A study examining the attitudes of medical residents at Louisiana State University Health
Sciences Center-Shreveport identified several barriers to physician provision of weight loss
counselling to patients. The barriers included pessimism about patient’s desire to lose weight and
the effectiveness of weight loss counselling, lack of obesity management resources, insufficient
time, deficits in brief counselling skills, and a lack of knowledge about best clinical practices in
this area. Patient surveys revealed that the majority of patients (60-65%) believe that their weight
affects their health and recognize that losing 10% of their weight would improve their health.
Additionally, 89% of patients reported a need to lose weight, 88% reported the desire to lose
weight, and 90% reported previous weight loss attempts (Huang, Marin, Brock, Carden, &
Davis, 2004). These data suggest that patients are invested in losing weight and would likely be
receptive to weight loss recommendations from their physicians.
However, while 79% of patients reported being counselled by their physician to lose
weight, only 28% reported being given specific weight loss recommendations concerning
modifications to their diet and/or activity or information about pharmacological or surgical
weight loss options. Only 5% of these patients recalled being given the combined weight loss
strategy of diet and exercise. Not surprisingly, patients who reported receiving weight loss
counselling from their physicians were more likely to have a better understanding of obesity
10

associated health problems and the benefits of weight loss, a stronger desire and increased
readiness for weight loss, and were more likely to be engaged in current or past weight loss
activities (Huang, Marin, Brock, Carden, & Davis, 2004). These data suggest that specific diet
and exercise recommendations, though infrequently provided by physicians, can positively
impact patient levels of motivation and accountability as well as their understanding of obesity.
Few research studies have found evidence to support the delivery of low to moderate
intensity lifestyle interventions, in person or over the phone, to overweight or obese adults by
primary care staff alone (Carvajal, Wadden, Tsai, Peck, & Moran, 2013; U.S. Department of
Health and Human Services, 2013). There is some support for the delivery of moderate-intensity
lifestyle interventions by trained professionals in group or individual formats on a bi-weekly to
monthly basis over a period of 6-12 months (U.S. Department of Health and Human Services,
2013). There is also evidence that weight loss medication or collaboration from other health
professionals, in addition to brief PCP counseling, produces increased weight loss (Carvajal,
Wadden, Tsai, Peck, & Moran, 2013). However, more intensive interventions may not be
feasible in primary care settings and additional health professionals and services may not be
easily accessible or available for many patients.
Tsai and Wadden (2009) reviewed 10 randomized controlled trials (RCTs) evaluating the
delivery of behavioral weight loss interventions alone or in combination with pharmacotherapy
in primary care settings. None of the four studies involving only mild to moderate intensity
lifestyle counseling delivered by a PCP resulted in weight loss that reached the threshold of
clinical significance, which is generally considered to be 3kg. These interventions involved the
creation of individualized behavioral goals through PCP visits occurring every 1-3 months,
however, none of them included any patient feedback or additional follow-up contact between
11

office visits. Two of the studies reviewed were able to achieve clinically significant weight loss
by combining low intensity lifestyle counseling by a PCP with pharmacotherapy. Another study
attained clinically significant weight loss by adding meal replacements and additional counseling
with a registered dietician.
Another review of 12 RCTs examining behavioral treatment of obesity in primary care
settings was conducted by Wadden, Butryn, Hong, and Tsai (2014). In all trials, lifestyle
counseling (including diet, exercise, and behavioral strategies) was provided for at least 3
months with at least 6 months of follow-up. Interventions were delivered by PCPs and/or trained
interventionists in person, by phone, or over the internet. Interventions involving only PCP
delivered diet and/or exercise focused counseling, and the use of motivational interviewing
strategies to assess patient readiness for change, did not achieve significant weight loss (>3kg) at
6 months. The interventions that were successful in achieving significant weight loss at 3
months, and maintenance at 6 months, were those in which comprehensive lifestyle interventions
were delivered by trained professionals with little PCP collaboration and supported by additional
resources. Many of the interventions that were able to achieve clinically significant weight loss
also involved additional participant contact between physician office visits. This review
highlights the fact that behavioral counseling, delivered by a variety of different trained
professionals (e.g., medical assistants, dieticians) in a variety of different formats (e.g., phone,
internet, in person), can produce clinically significant weight loss for primary care patients.
One pilot study combining behavioral counseling with pharmacotherapy demonstrated
initial support for structured lifestyle modification provided by PCPs during regular office visits.
Twenty-six obese women were prescribed two weight loss medications and assigned to receive
either 32 (75-minute) sessions of group behavior modification with a nutritionist or 10 (15-20
12

minute) physician visits that included lifestyle modification. After one year, both groups had
achieved significant and equivalent weight loss (30-34 pounds) and 96% of study participants
had lost 5-25% of their initial body weight. Treatment was also associated with significant
improvements in triglycerides, total cholesterol, HDL and LDL, resulting in decreased risk for
coronary heart disease. Additionally, participants reported significant improvements in mood,
attention, appetite, and eating behavior (Wadden, Berkowitz, Vogt, Steen, Stunkard, & Foster,
1997). These results suggest that frequent, structured, lifestyle modification provided by PCPs, in
combination with medication, may produce clinically significant weight loss and improvement in
obesity related health conditions. However, without the inclusion of a control group, it is not
clear which, if any, intervention components were actually responsible for the observed results.
The POWER-UP studies, conducted by the National Heart, Lung, and Blood Institute,
found that PCPs working with Medical Assistants (MAs) can deliver effective weight
management interventions to some obese patients in primary care settings. The delivery of brief
education and handouts provided by PCPs every three months resulted in ≥5% weight loss for
22% of participants. In comparison, the most intensive intervention, which included the addition
of monthly 10-15 minute phone calls with an MA and the choice of either meal replacement or
weight loss medication, resulted in ≥5% weight loss for 35% of participants (Wadden et al.,
2013). These results suggest that lifestyle modification delivered by PCPs in primary care
settings can result in significant weight loss for a subset of obese patients. More research is
needed to assess the feasibility of delivering these interventions in primary care and to determine
which patients are most likely to benefit.
A recent study conducted by Tsai et al. (2013) examined the cost effectiveness of primary
care treatment of obesity. Six primary care practices were examined and 390 patients with BMIs
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between 30 and 50, elevated waist circumference, and the presence of at least one metabolic
condition (high blood pressure, elevated triglycerides, low HDL cholesterol, impaired fasting
glucose/diabetes) were randomized to receive one of three treatments. The usual care (UC)
condition involved quarterly PCP visits. The brief lifestyle counseling (BLC) condition involved
quarterly PCP visits plus monthly weight loss counseling visits. Finally, the enhanced brief
lifestyle counseling (EBLC) condition involved the addition of the participant’s choice of either
weight loss medication or meal replacements. Participant weight and the cost for all intervention
components and concomitant medication use and other health care costs were measured.
Intervention costs were $3092 for EBLC, $1323 for BLC, and $837 for UC. The UC condition
had significantly higher costs associated with concomitant medications than the other groups,
however, no cost differences were observed between groups for other health care costs. Average
weight loss after two years was 1.7kg for UC participants, 2.9kg for BLC participants, and 4.6kg
for EBLC participants. Incremental cost-per-kilogram year lost for EBLC over UC was $292.
Incremental cost per QALY (quality adjusted life years) was $115,397 (no difference between
groups). These data suggest that primary care obesity treatment could be cost effective long-term
(Tsai et al., 2013).
Federal guidelines recommend the delivery of comprehensive lifestyle interventions, yet
there is limited research examining the effectiveness and feasibility of delivering these
interventions within primary care settings. Thus far, limited success has been achieved through
the provision of behavioral weight loss counseling by PCPs and other health providers in primary
care practices (Carvajal, Wadden, Tsai, Peck, & Moran, 2013). The best results have been found
with interventions involving frequent, face-to-face contact, however, this is difficult to achieve in
primary care settings (Ryan, 2016). In-person low intensity or remotely delivered high-intensity
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behavioral interventions typically result in less weight loss, however, they are also less resource
intensive and more accessible (Carvajal, Wadden, Tsai, Peck, & Moran, 2013).
Current Study
The currently available research evidence provides only limited data to support the
efficacy, feasibility, and cost-effectiveness of mild to moderate intensity behavioral interventions
delivered by PCPs. Most interventions involving only PCP delivered behavioral counseling,
without the addition of weight loss medication, additional resources, or interventions provided by
other trained professionals, have not achieved clinically significant weight loss. However, while
effective, the addition of these extra services requires increased time, cost, and staff demands,
which may not be feasible for many primary care practices.
PCPs play a critical role in identifying obesity, evaluating its causes, prescribing and
monitoring medications, assessing and treating co-morbid health conditions, and monitoring the
resulting outcomes. PCPs have the ability to reach large and diverse segments of the population
and prevent increasingly severe obesity and associated health conditions. Therefore, additional
research on the effectiveness of brief, structured lifestyle interventions delivered by PCPs is
warranted. However, consideration must also be given to feasibility, considering the limitations
of primary care practice and the barriers currently impacting the delivery of lifestyle
interventions by PCPs. Self-monitoring and regular feedback/follow-up are components known
to be effective in enhancing behavioral change and can be delivered electronically between
office visits to reduce burden. There is some research support for the electronic delivery of
obesity interventions and the potential to reduce time, cost, and resource burdens, which is
especially important in primary care settings.
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The current study examines both the feasibility and effectiveness of a brief behavioral
intervention for obesity and associated health conditions delivered by PCPs during scheduled
office visits and supported by at home participant behavior tracking and regular electronic
feedback from physicians. Brief physician training in the delivery of behavioral lifestyle
modification was provided to minimize the frequently cited barriers of knowledge and
confidence deficits. Electronic physician-patient between visit check-ins were utilized as a cost
and time effective alternative to high intensity face-to-face interventions to increase patient
compliance and outcomes. The use of brief, low-intensity, PCP delivered behavioral
interventions for obesity creates the base for a tiered model of care involving the widespread use
of available and accessible lifestyle interventions with minimal intrusiveness and risk as first-line
treatments. This would reserve the use of more intensive, costly, and risky interventions for more
severe and treatment resistant cases of obesity, in accordance with existing treatment guidelines.
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METHOD
Participants
All participants were recruited from an outpatient internal medicine primary care office.
All obese or overweight patients (BMI of 25+), who were at least 18 years of age, fluent in
English, and active members of the electronic communication system (MyChart) utilized in the
office as part of the electronic medical record (EMR), were eligible to participate. Patients
meeting these eligibility criteria, whose PCP was one of the physicians involved in the study, and
who were scheduled for an obesity related chronic health condition (i.e. diabetes, hypertension,
hyperlipidemia, sleep, depression, chronic pain) follow-up visit or yearly physical during the
recruitment period were contacted regarding participation in the study. All women who were
known to be pregnant were excluded from participating due to the potential risks associated with
weight loss during pregnancy.
All participants meeting the above criteria were sent an electronic message via the
MyChart system. The recruitment message (Appendix D) provided general information about the
study. Patients were asked to respond to this initial message if they were interested in receiving
additional information about study participation. Patients who did not wish to participate could
either send a message back declining participation or simply choose not to respond to the
recruitment message. Only patients who expressed explicit interest in participating via a reply
message were sent the full informed consent document (Appendix A) via MyChart. Potential
participants were given the opportunity to ask any questions they had about the study via
MyChart prior to providing consent. Additionally, the office manager, hospital risk management
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staff, and HSIRB staff were involved as needed to address participant questions and concerns.
Consent for participation was obtained through a MyChart message response to the informed
consent document that included a statement of understanding and intent to participate as well as
the patient’s full typed name. Once consent was received, participants were notified
electronically that they would be asked to complete a few brief questionnaires at their upcoming
office visit. All relevant future office visits were then flagged in the EMR (using documentation
in the appointment notes section) to alert office staff of study participation.
Procedures
All eligible participants who consented to participate in the study completed a brief
questionnaire assessing sleep quality and a PHQ-9 to assess depression symptoms while waiting
to be seen by their physician for their regularly scheduled office visit occurring during the study
recruitment period. Data were then collected at all relevant office visits occurring over a 13month period between April 2017 and May 2018 with the goal of obtaining data at two different
time points for each participant. At each office visit participants completed the sleep quality
questionnaire and the PHQ-9 while waiting to be seen by their physician. All relevant
physiological measures (weight, BMI, blood pressure, cholesterol, hemoglobin A1c) collected at
office visits as part of routine clinical care were retrieved from the EMR.
All standard office policies were followed in the event of medical or mental health
emergencies. There was a social worker available in the office at all times to assist in the event
that significant mental health symptoms or suicidal ideation were endorsed by participants on the
PHQ-9. This did not occur during the course of the study. In keeping with standard care,
physicians reviewed participant PHQ-9 data at each office visit and referred patients with
significant depression symptoms to the medical social worker for follow-up care as appropriate.
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Two physicians (one male and one female) were selected to provide a brief behavioral
intervention to their consenting patients who met the inclusion criteria, and two different
physicians (one male and one female) were selected to continue providing their usual level of
patient care to their consenting patients who met the inclusion criteria. Usual physician care for
obesity involved checking BMI at every office visit and offering BMI counseling once/year.
Participant assignment to receive either brief behavioral treatment or usual care was determined
by the role assigned to their pre-existing PCP. Participants in the behavioral intervention
condition were compared to participants who continued to receive usual physician care without
modification during the data collection period. All physicians consented to their role in the
research study and were instructed in how to perform their role prior to study initiation.
Behavioral Intervention
The same physiological and self-report data were collected for participants in both the
usual care and behavioral intervention conditions at all scheduled office visits occurring during
the data collection period. However, participants in the behavioral intervention condition also
completed a brief questionnaire assessing their current eating and exercise habits (Appendix C)
at their initial office visit as well as all subsequent office visits during the study. Physicians
administering the behavioral intervention spent five minutes during the initial visit reviewing the
completed diet and exercise habits questionnaire with participants and utilizing it to assist them
in collaboratively setting one specific behavioral goal for improving diet and one specific
behavioral goal for improving physical activity. Goals were recorded in visit progress notes and
check-out instructions, using standardized templates, to track PCP treatment adherence and to
serve as a reminder for participants.
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Following the initial office visit, participants in the behavioral intervention condition
were sent a MyChart message containing instructions about completing behavioral tracking and
regular electronic reporting of progress to PCPs (Appendix F). Participant progress towards diet
and exercise goals was reviewed with physicians during all subsequent office visits occurring
during the data collection period. Between office visits, patients in the behavioral intervention
condition were asked to track their diet and physical activity and send their physician brief
summaries of their progress towards their behavioral goals and a current weight via MyChart.
Physicians, with the help of medical assistants as needed, provided brief responses to patient
updates either encouraging continued progress or troubleshooting barriers and suggesting
modifications. Physicians were able to use response templates within the EMR system to respond
to participant check-in messages. Physician-patient exchanges were scheduled to occur
once/week following the first office visit, once every two weeks following the second office visit
or after three months of weekly check-ins, and once/month following any additional office visits
that occurred during the data collection period or after three months of bi-weekly check-ins.
Participants were prompted via MyChart to send progress summaries to their physicians
at the specified time points. If on any occasion participants failed to send progress summaries to
their physician by the appropriate date, up to three reminder prompts were sent via MyChart.
Any participants who failed to provide MyChart check-ins at three consecutive time points,
despite receiving multiple reminders, were no longer prompted to send MyChart check-ins at
future time points. In person self-report and physiological data continued to be collected at all
office visits regardless of whether or not participants were compliant in providing regular
between visit MyChart updates.
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The two physicians delivering the behavioral intervention attended a brief training prior
to the start of data collection. This training involved a review of possible diet and exercise goals
and behavioral principles/strategies involved in setting, modifying, and troubleshooting specific
diet and exercise goals as outlined in the physician decision guide (Appendix E). If physicians
delivering the behavioral intervention failed to document participant goals in the chart or failed
to respond to participant MyChart check-in messages within one week they were reminded to
engage in these practices.
At the conclusion of the data collection period, consumer satisfaction data were collected
from both PCPs and patients who delivered and/or received the brief behavioral intervention.
Participants were asked to complete a brief 3-item questionnaire assessing the utility and
feasibility of the behavioral intervention (Appendix G) either during their final office visit or via
MyChart. Physicians were asked to complete either a paper and pencil or electronic version of
the questionnaire at the end of the study.
Measures
Primary Outcomes: Obesity and Associated Health Conditions
Physiological measures. Prior to many yearly physical or chronic health condition
follow-up appointments patients will have relevant lab work done (in keeping with standard
clinical practice), including hemoglobin A1c and cholesterol. Additionally, at every office visit
height, weight, BMI, and blood pressure are recorded. These routine progress measures were
retrieved from the EMR and used to measure the presence/severity of obesity related health
conditions (e.g. hypertension, diabetes, hyperlipidemia). Usual physician care was not modified
with respect to medications, procedures, lab work, or scheduling. Thus, there were no additional
costs to participants that would not ordinarily be part of usual physician care outside of the study.
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Mood. Depression is known to be prevalent among obese individuals seeking weight loss
treatment (Anderson, & Wadden, 1999) and previous research has shown that decreases in
depression can occur alongside successful weight loss (Wadden, Berkowitz, Vogt, Steen,
Stunkard, & Foster, 1997). Therefore, depression levels were measured at all office visits
occurring during the data collection period using the PHQ-9. This is a 9-item questionnaire
designed to measure depression levels in medical settings. The PHQ-9 was already being used in
the office as a depression screening tool prior to study initiation so it was easily available,
familiar to staff, and part of the existing office work flow. It takes less than 5 minutes to
complete and has been found to have diagnostic validity (Spitzer, Kroenke, & Williams, 1999).
Participants completed the PHQ-9 while waiting to be seen by their physician at each office visit.
Total PHQ-9 scores were used as an outcome measure in the current study.
Sleep. Sleep issues have been found to commonly co-occur with obesity (Aronne, 2001;
Must et al., 1999; National Heart, Blood, and Lung Institute, 2001). Twelve questions, derived
from evidence-based recommendations for assessing sleep (Bloom et al., 2009), were utilized to
assess the quality of participant sleep throughout the study (Appendix B). This questionnaire was
administered at all office visits occurring during the data collection period. Participants
completed the sleep questionnaire at each visit while waiting to be seen by their physician. The
total number of items endorsed as a “yes” (out of a possible 9 questions) was used as an outcome
measure of overall sleep quality, with higher numbers indicating poorer sleep quality.
Secondary Outcomes: Behavioral Intervention
Diet and exercise habits. At the initial office visit occurring during the recruitment
period, participants in the behavioral intervention condition completed a questionnaire assessing
their current level of motivation and willingness to try a variety of different diet modification
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strategies and physical activity changes (Appendix C). This information was used to assist
physicians in selecting specific diet and exercise goals that were individually relevant for each
participant. This questionnaire was also completed at all additional follow-up visits that occurred
during the data collection period to assist PCPs in monitoring participant progress towards
existing goals and establishing new goals as needed. Data were not used in any formal analyses.
Treatment adherence. Physicians were asked to record the specific diet and exercise
goals set with participants receiving the behavioral intervention during the initial office visit in
their EMR notes. The percentage of initial office visit notes including specific goals was used as
a measure of treatment adherence for PCPs delivering the behavioral intervention. The number
of MyChart follow-up messages exchanged between participants and PCPs was used as an
additional measure of treatment adherence for the behavioral intervention group.
Consumer satisfaction. At the completion of the data collection period, both physicians
and participants in the treatment condition were asked to complete a brief 3-item measure
assessing the utility and feasibility of the behavioral intervention (Appendix G). Each question
was rated on a 1 (strongly disagree) to 5 (strongly agree) scale, resulting in 15 total possible
points. Both paper and pencil and electronic versions of the questionnaire were available.
Numerical ratings as well as qualitative comments were recorded and analyzed.
Study Design
The first stage of the study involved the recruitment of participants. All regularly
scheduled obesity related chronic health condition follow-up or yearly physical visits occurring
over a one-month period were screened for eligible participants who met study inclusion criteria.
Treatment condition (usual care or behavioral intervention) was determined by the pre-existing
assigned PCP for each participant. Participants were followed for up to 12 months after their
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initial office visit and entry into the study. Relevant and available physiological measures as well
as mood, sleep quality, and diet/exercise habits (behavioral intervention condition only)
questionnaires were completed at all office visits occurring during the data collection period.
Data was collected at all office visits for participants in the behavioral intervention condition
regardless of compliance with the between visit MyChart physician check-ins.
Data Analysis
Descriptive statistics were utilized to characterize participant demographics, treatment
adherence, and consumer satisfaction data. Pretreatment differences between the usual care and
behavioral intervention conditions were analyzed using Pearson’s chi-square tests and
independent measures t-tests.
Between group outcome analyses were conducted on an intent-to-treat sample using the
Linear Mixed Models procedure in SPSS, version 24. A mixed models framework was selected
because it does not require repeated measures data to be collected at equal timepoints across all
participants and it allows for the inclusion of cases with missing data. A correlated random
effects model was utilized with participant I.D. entered as the subject variable. Treatment
condition, time, and treatment condition*time interactions were entered as fixed factors. Random
factors included participants entered as a subject grouping. Time was recorded as number of
months since baseline which resulted in rates that reflect the amount of change/month for all
outcome variables. All outcome measures were analyzed individually using an unstructured
covariance model.
Effect size analyses were calculated using Cohen’s d for all dependent variables to assess
the amount of clinically significant change achieved. Last available outcome data from the
behavioral intervention group were contrasted with last available outcome data from the usual
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care group. For participants in the behavioral intervention condition only, bivariate Pearson
product-moment correlations were used to analyze the relationship between outcome variables
and degree of treatment adherence, as measured by the number of MyChart messages exchanged
between participants and providers.
All participants were included in analyses as long as they received either the behavioral
intervention or usual care and contributed outcome data during at least one time point throughout
the study. Every effort was made to obtain outcome data at two or more time points from as
many participants as possible. Of the 291 eligible patients contacted about participation in the
study during the recruitment period, 33 (11.34%) consented to participate (see Figure 1). The
majority of those who did not participate, never responded to the initial MyChart message about
the study. Of the 33 participants who consented to participate, data from 32 were used in final
analyses. One participant was excluded from receiving the behavioral intervention due to PCP
concerns regarding the appropriateness of weight loss given the patient’s age and BMI.
Over the course of the 12-month data collection period, data were obtained at two or
more time points from 29 participants. Data were obtained only during an initial office visit for
the remaining three participants. One of these three participants chose to voluntarily withdraw
following the initial office visit, and thus no further data was collected. The other two
participants never attended a follow-up visit during the data collection period. Additionally, one
participant received bariatric surgery and another became pregnant during the course of the study
so only data collected prior to these events were utilized in analyses.
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Participant Flow Diagram

Enrollment

Assessed for eligibility (n=291)

Excluded (n=258)
 Did not volunteer to participate
(n=258)

Assigned to Condition (n=33)

Allocation
Allocated to behavioral intervention (n=16)
 Received allocated intervention (n=15)
 Did not receive allocated intervention
(excluded for safety; n=1)

Allocated to usual care (n=17)
 Received allocated intervention (n=17)
 Did not receive allocated intervention (n=0)

Follow-Up
Lost to follow-up (no return office visit; n=1)
Discontinued intervention (had bariatric
surgery or withdrew; n=2)

Lost to follow-up (no return office visit; n=1)
Discontinued intervention (became pregnant
during study; n=1)

Analysis
Analysed (n=15)
 Excluded from analysis (excluded from
receiving intervention; n=1)

Analysed (n=17)
 Excluded from analysis (n=0)

Figure 1. Participant Flow Diagram
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RESULTS
Demographics and Pre-Treatment Variables
Of the final sample of 32 participants, 15 (47%) received the brief behavioral intervention
and 17 (53%) received usual care. At baseline, 25% of the total sample was overweight and 75%
was obese (see Figure 2). There were a total of 9 (28%) male (n = 5 intervention; n = 4 usual
care) and 23 (72%) female participants (n = 10 intervention; n = 13 usual care). The average age
of the entire sample was 54.69 years (SD = 14.85, range = 27–78). Participants in the
intervention group were slightly older (M = 57.53, SD = 14.69) than participants in the usual
care group (M = 52.18, SD = 14.97). Male participants (M = 62.22, SD = 15.44) were also
slightly older than female participants (M = 51.74, SD = 13.84). There were no statistically
significant differences between participants in the behavioral intervention and usual care
conditions on any of the demographic or outcome variables at baseline (see Table 1).
Table 1
Pre-treatment Differences for Demographic and Outcome Variables
____________________________________________________________________________________
Variable
t
p
Variable
t
p
____________________________________________________________________________________
Age
-1.019
0.316
LDL Cholesterol
2.151
0.051
Weight

0.696

0.492

Cholesterol Ratio

1.736

0.106

BMI

-0.417

0.680

Systolic BP

-1.670

0.105

Hemoglobin A1c

-0.400

0.703

Diastolic BP

1.368

0.181

Total Cholesterol

1.660

0.121

Sleep Quality

0.697

0.491

Triglycerides

0.862

0.404

Depression

0.532

0.599

HDL Cholesterol

-1.269

0.227

*Gender

0.379

0.538

_____________________________________________________________________________________
Note. *=nominal variable for which Pearson chi-squared (𝑥 2 ) analysis was used instead of independent
measures t-test analysis; BP = blood pressure; BMI = body mass index.

27

Figure 2. Baseline Frequency of BMI Categories
Treatment Adherence
The number of office visits attended by participants during the course of the study was
similar across both the behavioral intervention and usual care groups (see Figure 3). Treatment
adherence data was collected in order to monitor the degree to which participants in the
behavioral intervention condition received important additional intervention components.
Specific diet and exercise goals were recorded by physicians in EMR visit notes for all but one
(14/15) eligible initial office visit with participants in the behavioral intervention group. This
represents a 93.3% adherence rate. Participants in the intervention group sent their physicians an
average of 7.6 (SD = 9.66) MyChart message updates regarding weight loss and progress
towards diet and exercise goals during the course of the data collection period. The number of
MyChart messages sent by individual participants ranged from zero to 28.
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Figure 3. Number of Office Visits Attended by Participants Throughout the Study
In order to evaluate whether a dose-response relationship was present in the behavioral
intervention condition between any of the outcome variables and the number of MyChart
exchanges that occurred, bivariate Pearson product-moment correlation analyses were conducted
(see Table 2). No relationship was found between weight, BMI, triglycerides, or diastolic blood
pressure and number of MyChart messages exchanged. A weak relationship was found between
HDL cholesterol, systolic blood pressure, sleep quality, depression and MyChart messages
indicating that as the number of MyChart messages increased, depression, sleep quality, and
HDL cholesterol improved, whereas systolic blood pressure worsened. A medium strength
relationship was found between total cholesterol, cholesterol ratio, LDL cholesterol and MyChart
messages, indicating that as the number of MyChart exchanges increased, scores on these
variables improved (decreased). Finally, a strong relationship was observed between hemoglobin
A1c and MyChart messages (r = -0.589), indicating improvement (decrease) in A1c values as the
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number of MyChart exchanges increased. Specifically, the number of MyChart messages sent
explains 34.7% of the variation in A1c values (𝑟 2 = 0.347).
Table 2
Pearson Correlation Coefficients for Number of MyChart Messages and Outcome Variables in the
Behavioral Intervention Group
_____________________________________________________________________________________
Variable
r
Variable
r
_____________________________________________________________________________________
Weight
0.072
LDL Cholesterol
-0.501
BMI

-0.034

Cholesterol Ratio

-0.426

Hemoglobin A1c

-0.589

Systolic BP

0.198

Total Cholesterol

-0.413

Diastolic BP

0.090

Triglycerides

0.041

Sleep Quality

-0.275

*HDL Cholesterol

0.136

Depression

-0.255

___________________________________________________________________________________
Note. Boldface values indicate strong correlations (r = 0.5-1.0); italicized values indicate medium
strength correlations (r = 0.3-0.5); BP = blood pressure; BMI = body mass index; *=higher scores
indicate improved outcomes (higher scores indicate worse outcomes for all other variables).

Linear Mixed Modeling
There were no statistically significant main effects of time, however, one statistically
significant treatment*time interaction effect was found in the linear mixed modeling analyses.
There was a statistically significant difference in the rate of change for A1c in the intervention
group relative to the usual care group (F = 5.20; p = .047). Specifically, A1c decreased over
time in the intervention group and increased over time in the usual care group (see Figure 4). The
overall numerical pattern of results is mixed across the remaining outcome variables (see Table
3). Decreased scores are associated with improvement across all outcome measures except for
HDL cholesterol where increased scores are associated with improvement.
For weight (see Figure 5), and to a lesser degree BMI (see Figure 6), rates of change
indicate numerical reduction (improvement) over time in both the intervention and usual care
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groups, with a trend towards greater improvement in the usual care group. The following
descriptive data was also obtained regarding clinically significant (≥3kg) weight loss over the
course of the study. In the intervention group, 4 participants (30.77% of those who had data
collected at multiple time points) achieved clinically significant weight loss. One of these four
participants lost more than 10% of initial body weight. In the usual care group, 5 participants
(31.25% of those who had data collected at multiple time points) achieved clinically significant
weight loss. Four of these five individuals also lost 5-10% of their initial body weight.
Numerical rates of change for total cholesterol (see Figure 7) indicate relative stability/
slight reduction (improvement) over time for the usual care group compared with a trend towards
more substantial reduction in the intervention group. Numerical rates of change for triglycerides
(see Figure 8) indicate an upward (worsening) trend over time in the usual care group compared
with a downward (improving) trend over time in the intervention group. Numerical rates of
change for systolic blood pressure (see Figure 9) and depression (see Figure 10; approaching
statistical significance) indicate relative stability/slight increase (worsening) over time for the
usual care group compared to a trend towards reduction (improvement) in the intervention group.
For HDL cholesterol (see Figure 11) and diastolic blood pressure (see Figure 12), the
numerical rates of change indicate a trend towards worse outcomes over time, more so in the
intervention group than the usual care group. Numerical rates of change for cholesterol ratio (see
Figure 13) reveal overall stability with a very slight trend towards worse outcomes for both
groups over time, particularly the usual care group. Rates of change for LDL cholesterol (see
Figure 14) and sleep quality (see Figure 15) reveal a numerical upward (worsening) trend for the
intervention group and a downward (improving) trend for the usual care group.
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Figure 4. Individual Hemoglobin A1c Values Over Time

Figure 5. Individual Weight Values Over Time
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Figure 6. Individual BMI Values Over Time

Figure 7. Individual Total Cholesterol Values Over Time
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Figure 8. Individual Triglyceride Values Over Time

Figure 9. Individual Systolic Blood Pressure Values Over Time
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Figure 10. Individual PHQ-9 Values Over Time

Figure 11. Individual HDL Cholesterol Values Over Time
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Figure 12. Individual Diastolic Blood Pressure Values Over Time

Figure 13. Individual Cholesterol Ratio Values Over Time
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Figure 14. Individual LDL Cholesterol Values Over Time

Figure 15. Individual Sleep Quality Values Over Time
37

Two representative case examples of participants in the behavioral intervention group
(with the same PCP) are presented to illustrate changes in weight and associated health
conditions over the course of the study. The first is a 69-year-old female who attended three
office visits (baseline, 3 months, and 12 months) and exchanged 28 MyChart messages with her
PCP. Her weight dropped from 261 lbs. at baseline to 250 lbs. 12 months later at her final office
visit. This represents an overall weight loss of 11 lbs. or just over 4% of her initial body weight.
Her BMI went from 44.73 at baseline to 41.6 at 12 months. While she remained in the most
severe category of obesity throughout the study (BMI ≥40), she was able to lower her BMI by
several points. Additionally, her cholesterol values at baseline were: total:169, triglycerides: 135,
HDL: 82, LDL: 60, and ratio: 2.1. At her 12-month follow-up visit her cholesterol values were:
total: 143, triglycerides: 105, HDL: 66, LDL: 56, and ratio: 2.2. These values reflect a decrease
across total cholesterol, triglycerides, and LDL, all of which reflect improvement and decreased
risk of heart disease. While HDL cholesterol also decreased, and her ratio increased slightly,
which reflect changes in the undesired direction, all cholesterol values were within normal range.
Blood pressure was 130/84 at baseline and 124/74 at 12 months, revealing improvement in both
systolic and diastolic blood pressure throughout the study. No A1c values were collected. Sleep
quality and depression scores both decreased from a value of 1 at baseline to a value of 0 at 12
months, revealing an absence of sleep and depression concerns. She completed the consumer
satisfaction survey at the conclusion of the study and gave the intervention the highest rating of 5
across all categories, resulting in a total score of 15/15. Additionally, she commented: “I became
more focused and motivated to change my behavior.”
Another case is that of a 37-year-old female who had two office visits (baseline and 12
months) but did not send any between-visit MyChart check-ins to her PCP during the course of
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the study. Her weight went from 203 lbs. at baseline to 210 lbs. at 12 months. This reflects an
overall weight gain of 7 lbs. or 3.4% of her initial body weight. BMI went from 35.96 at baseline
to 37.8 at 12 months, moving her closer to the severe obesity range. Her blood pressure went
from 112/74 to 128/84, demonstrating worsening of both systolic and diastolic blood pressure
from baseline to 12-month follow-up. No A1c data was collected. Cholesterol values were not
collected at baseline, however, values at 12 months were: total: 198, triglycerides: 72, HDL: 51,
LDL: 133, ratio: 3.9. These values reveal low HDL and elevated LDL and ratio values. In
contrast to poor physical health outcomes, both sleep quality and depression scores improved
over the course of the study, moving from 4 to 2 and 3 to 0 respectively. She also completed the
consumer satisfaction survey and rated the intervention 3/5 in terms of usefulness/helpfulness,
4/5 in terms of feasibility, and 3/5 in terms of likelihood of recommending this intervention to
others. This resulted in a total score of 10/15 accompanied by the following comment: “I lacked
follow through.” In summary, these case studies provide additional qualitative evidence for the
important role that participant engagement and frequent between-visit check-ins can play in
improving outcomes.
Table 3
Fixed Effect Estimates from Intent-to-Treat Analyses Using SPSS Linear Mixed Modeling
_____________________________________________________________________________________
Intercept Condition
Time Main Effect
Condition*Time Interaction
Variable
F
p
F
p
_____________________________________________________________________________________
Weight
(n = 90)
BMI
(n = 90)
Hemoglobin A1c
(n = 21)
Total Cholesterol
(n = 31)
Triglycerides
(n = 31)

220.075

-8.114

-0.322

7.754

0.191

0.139

0.174

0.678

34.265

0.874

-0.040

0.660

0.420

0.008

0.012

0.912

5.859

0.849

0.048

2.731

0.132

-0.104 5.200

0.047

198.391

-21.462

-0.015

0.000

0.990

-0.357 0.032

0.862

136.201

-25.947

1.452

0.511

0.487

-3.105 0.808

0.383
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Table 3 – continued
*HDL Cholesterol
56.239
4.425
-0.160 0.231 0.640
-0.320 0.310 0.588
(n = 31)
LDL Cholesterol
115.144
-20.742
-.0.175 0.032 0.862
0.623 0.140 0.715
(n = 31)
Cholesterol Ratio
3.711
-0.622
0.010
0.109 0.746
-0.004 0.007 0.934
(n = 31)
Systolic BP
122.768
6.169
0.031
0.011 0.917
-0.341 0.715 0.401
(n = 90)
Diastolic BP
77.711
-2.114
0.188
0.601 0.441
0.177 0.285 0.595
(n = 90)
Sleep Quality
2.442
-0.299
-0.085 2.433 0.128
0.090 1.596 0.215
(n = 62)
Depression
6.099
-1.226
0.011
0.011 0.917
-0.260 3.321 0.076
(n = 71)
___________________________________________________________________________________
Note. Boldface values reflect statistical significance (p<.05); italicized values reflect approaching
statistical significance; BP = blood pressure; BMI = body mass index; n = sample size; * = higher scores
indicate improved outcomes (higher scores indicate worse outcomes for all other variables)
Table 4
Effect Sizes for Dependent Variables
_____________________________________________________________________________________
Variable
Usual Care
Behavioral Intervention
Cohen’s d
n
Mean (SD)
n
Mean (SD)
_____________________________________________________________________________________
Weight
17
217.18 (34.23)
15
210.33 (30.60)
-0.21
BMI

17

33.86 (4.40)

15

34.92 (5.56)

0.21

Hemoglobin A1c

5

6.26 (1.25)

5

6.42 (1.51)

0.12

Total Cholesterol

12

196.42 (37.82)

8

174.63 (39.92)

-0.56

Triglycerides

12

144.25 (83.27)

8

100.00 (28.94)

-0.71

*HDL Cholesterol

12

55.33 (13.80)

8

57.88 (14.28)

0.18

LDL Cholesterol

12

112.17 (32.59)

8

96.88 (36.50)

-0.44

Cholesterol Ratio

12

3.72 (1.07)

8

3.10 (0.65)

-0.69

Systolic BP

17

123.18 (11.73)

15

127.07 (12.00)

0.33

Diastolic BP

17

80.12 (8.96)

15

80.00 (6.76)

-0.01

Sleep Quality

17

1.82 (1.55)

15

2.20 (1.74)

0.23

Depression

17

6.06 (6.15)

15

2.40 (3.29)

-0.74

___________________________________________________________________________________
Note. Boldface values indicate medium effect size (Cohen’s d: 0.2 = small, 0.5 = medium, 0.8 = large
effect); BP = blood pressure; BMI = body mass index; SD = standard deviation; n = sample size;*=higher
scores indicate improved outcomes (higher scores indicate worse outcomes for all other variables)
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Effect size analyses (see Table 4) revealed no effect for Hemoglobin A1c, HDL
cholesterol, or diastolic blood pressure and only a small effect for weight, BMI, LDL cholesterol,
systolic blood pressure, and sleep quality. Medium sized effects were found for total cholesterol,
triglycerides, cholesterol ratio, and depression. No large effect sizes were found for any of the
dependent variables measured in the study.
Consumer Satisfaction
Qualitative and quantitative (see Table 5) consumer satisfaction data was obtained from
both physicians and participants involved in the behavioral intervention. Each of three questions
was rated on a 1 (strongly disagree) to 5 (strongly agree) scale, resulting in a total of 15 possible
points. Ratings from the two physicians who delivered the intervention revealed an average
rating of 4.0 (SD = 1.41) for the degree to which they found the intervention to be useful, 4.5
(SD = 0.71) for the degree to which the intervention was manageable in terms of time
requirements, and 4.0 (SD = 1.41) for the likelihood that they would recommend this
intervention to others. The average of their overall total satisfaction ratings was 12.5 (SD =
3.54). Individual comments revealed that it took approximately 15-30 seconds to respond to
individual patient MyChart messages. One physician reported feeling that the intervention
“helped to keep in touch with patients who were motivated and working toward a behavioral
goal.” This physician also noted that the individual follow-up was not burdensome due to the low
number of patients who participated in the study.
Data was obtained from eight participants (53%) in the behavioral intervention group.
One participant answered only the first two questions, and another provided qualitative feedback
but no quantitative ratings. Therefore, complete data was obtained from 6 participants (40%).
Ratings revealed an average of 3.57 (SD = 1.13) for the degree to which they found the
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intervention to be useful, 4.29 (SD = 0.49) for the degree to which the intervention was
manageable in terms of time requirements, and 4.0 (SD = 0.89) for the likelihood that they would
recommend this intervention to others. The average of their overall total satisfaction ratings was
12.17 (SD = 2.32); however, these data are interpreted cautiously given the low response rate.
Individual comments revealed that the intervention was “painless, interesting, and beneficial” as
well as being helpful with “focus and motivation to change behavior.” One patient stated:
“talking to my doctor weekly, biweekly, or monthly was a great way to maintain an ongoing
conversation regarding goals, expectations, and successes.” Another patient acknowledged, “I
lacked follow through on this intervention.”
Table 5
Consumer Satisfaction Data from Physicians and Participants in the Behavioral Intervention Group
_____________________________________________________________________________________
Q1: Helpful/Valuable Q2: Reasonable/Manageable
Q3: Recommend
Total
M(SD)
M(SD)
M(SD)
M(SD)
Respondent
_____________________________________________________________________________________
Physicians (n = 2)

4.0(1.41)

4.5(0.71)

4.0(1.41)

12.5(3.54)

Participants (n = 7)
3.57(1.13)
4.29(0.49)
4.0(0.89)*
12.17(2.32)*
_____________________________________________________________________________________
Note. Each question was rated on a 1 (strongly disagree) to 5 (strongly agree) scale; Total score is out of
15; M = mean; SD = standard deviation; n = sample size; * = only 6 participant responses were recorded.
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DISCUSSION
Obesity is a chronic health condition that continues to increase in prevalence around the
world, despite the existence of several effective treatments. Obesity often presents first in
primary care and is typically managed by PCPs. Therefore, the current study examined both the
feasibility and effectiveness of a brief behavioral intervention for obesity and associated health
conditions that was delivered by PCPs during scheduled office visits and supported by at home
participant behavior tracking and regular electronic between-visit check-ins. Prior research has
provided only limited data to support the efficacy, feasibility, and cost-effectiveness of mild to
moderate intensity behavioral interventions delivered by PCPs (Carvajal, Wadden, Tsai, Peck, &
Moran, 2013). Though more effective, the delivery of high intensity behavioral interventions
requires additional time, cost, and staff demands, which may not be feasible for many primary
care practices (Ryan, 2016).
PCPs play a critical role in obesity management and thus consideration must be given to
the feasibility of delivering comprehensive lifestyle interventions in primary care. The current
study attempted to overcome many commonly cited barriers including lack of time, resources,
and knowledge (Kushner, 1995), through the use of brief physician training and regular
electronic check-ins. The low-intensity, brief behavioral intervention utilized in the current study
was designed as a first-tier treatment for obesity aimed at producing benefit while being low-risk
and using minimal resources. Weight loss among obese individuals is known to be associated not
only with decreased incidence of obesity but also a reduction in the incidence of obesity-related
health conditions (Moyer, 2012). Thus, the chronic health conditions most likely to present
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alongside obesity during PCP visits: hypertension, hyperlipidemia, diabetes, and depression
(Talwalkar & McCarty, 2016) were also targeted by the current intervention.
Though participants were not randomized to study conditions, sample size and participant
demographics (gender, age) were roughly equivalent across the behavioral intervention and usual
care groups in the current study. Overall, there were substantially more female than male
participants, however, participants were diverse in terms of age. There were no statistically
significant differences found between participants in the behavioral intervention and usual care
groups on any demographic or pre-treatment variables.
At baseline, 25% of the total sample had a BMI in the overweight range and 75% had a
BMI in the obese range. This suggests that, in additional to lifestyle modification, nearly all
study participants could likely be considered for the addition of other treatment components,
including pharmacotherapy or bariatric surgery, given their BMI and the presence of associated
health conditions, in accordance with national treatment guidelines (Arterburn & Courcoulas,
2014; Moyer, 2012; Ryan, 2016).
Treatment adherence data revealed that the behavioral intervention was implemented
with good fidelity by PCPs, though participants varied widely in completion of regular MyChart
check-ins as prescribed by the study. This variability could have impacted results, as regular
electronic follow-up with PCPs between office visits was conceptualized as an important
component of the behavioral intervention utilized in the current study. Correlational analyses
evaluating the degree to which variability in treatment adherence, as measured by quantity of
MyChart exchanges, explained any of the variation in outcome measures found mixed results.
Number of MyChart messages was found to have little to no relationship with weight, BMI,
triglycerides, HDL cholesterol, blood pressure, sleep, and depression. However, there was a
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medium strength negative relationship found for some cholesterol variables (total, LDL, and
ratio), and a strong negative relationship between MyChart messages and A1c values. This
suggests that an increase in the number of between visit check-ins between participants and their
PCPs is related to improvement on some outcome variables. Future studies should therefore
consider ways of increasing participant adherence to study requirements, such as providing
incentives, utilizing electronic tracking to monitor behavioral progress towards goals, or
investigating alternative forms of communication between participants and PCPs.
Linear mixed modeling analyses revealed mixed results overall with some evidence of
improved outcomes in the behavioral intervention group relative to the usual care group. Most
notably, a statistically significant improvement was observed in the rate of change over time for
hemoglobin A1c in the intervention group compared to the usual care group. This could be due
to the strong role of diet and exercise in diabetes management and the responsiveness of A1c
values to modifications in diet and physical activity. No other significant differences were found
among the rates of change over time for weight or other obesity-associated health conditions
between the behavioral intervention and usual care groups. However, some consistent trends can
be described among the pattern of results.
Weight and BMI demonstrated numerical trends towards improvement over time across
both groups, more so in the usual care group than in the intervention group, though there was not
a statistically significant time effect. Additionally, several variables, including systolic blood
pressure, triglycerides, total cholesterol, and depression, demonstrated numerical trends towards
improvement in the intervention group relative to the usual care group. However, the variables of
diastolic blood pressure, HDL cholesterol, LDL cholesterol, and sleep quality revealed numerical
trends towards worse outcomes in the intervention group relative to the usual care group.
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Interestingly, effect size analyses revealed no effect for HDL cholesterol, diastolic blood
pressure, and hemoglobin A1c. This suggests that, although a statistically significant difference
was found for hemoglobin A1c in the rates of change over time between the usual care and
behavioral intervention groups, this difference may not be clinically meaningful. However, the
number of available A1c values used in this analysis was very small. Small effect sizes were
found for: weight, BMI, LDL cholesterol, systolic blood pressure, and sleep quality and medium
sized effects were found for: total cholesterol, triglycerides, cholesterol ratio, and depression.
This indicates that, although statistically significant differences in rates of change over time
between the usual care and behavioral intervention groups were not found for these variables, it
is possible that the observed differences could be clinically meaningful. This is especially
relevant for depression scores, as linear mixed modeling analyses almost reached the level of
statistical significance and effect size analyses revealed a medium to large effect.
Descriptive statistics revealed that approximately the same percentage of participants
achieved clinically significant (≥3kg) weight loss across both groups (30.8% behavioral
intervention; 31.3% usual care), though more weight was lost overall in the usual care group.
This suggests that there were factors operating in the usual care group that were equally as
powerful as the individualized behavioral goal setting that occurred in the intervention group. It
also suggests that the brief behavioral intervention may produce significant weight loss and
improvement in a subset of the primary care population.
In comparison to the POWER-UP studies (Wadden et al., 2013), where 22% of
participants lost ≥5% of their initial body weight with brief education delivered by PCPs every 3
months, in the current study 1 participant in the behavioral intervention group (6.7%) and 4
participants in the usual care group (23.5%), or a total of 5 participants across both groups
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(15.6%), were able to achieve ≥5% weight loss. The lower percentages in the current study could
be a result of reduced visit frequency, as only 28% of participants in the current study attended
an office visit at least once every 3 months. Additionally, it appears that the usual care and
behavioral intervention conditions in the current study may not have been different enough from
each other, as they resulted in similar rates of clinically significant weight loss. In order to
maximize resources, future research should investigate for which subgroups brief behavioral
intervention is likely to be most effective.
Consumer satisfaction data obtained from both physicians and patients revealed a
relatively high degree of feasibility and acceptability for the brief behavioral intervention utilized
in the current study. Participant data was obtained both from those who were highly adherent and
sent their PCPs frequent MyChart check-in messages and those who were less adherent and sent
their PCP zero or very few MyChart messages throughout the study. This variability is also
reflected in participant comments (e.g., “I became more focused and motivated to change my
behavior” and “I lacked follow-through on this intervention”). Participant ratings ranged from 2
to 5 for the degree to which they found the intervention to be helpful/useful, however, all
participants rated the intervention highly (ratings of 4 or 5) in terms of feasibility. This is an
important consideration for future studies as it suggests that perhaps more intensive interventions
would be more helpful and also still be reasonably feasible for patients. However, it is notable
that majority of the participants in the behavioral intervention group did not complete the
consumer satisfaction survey, so the obtained data should be interpreted somewhat cautiously.
Those that chose to complete the survey may represent a biased or unrepresentative sample.
Physicians reported that the level of time required to respond to regular individual
patient messages was manageable and that the intervention was helpful in terms of staying in
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touch with patients. Of note, the PCP who had a larger number of patients participating in the
active treatment condition over the course of the study, provided slightly lower satisfaction
ratings on all items. This indicates that the degree to which physicians feel that the time required
to implement the intervention is feasible depends on the number of patients with whom they are
implementing the intervention at a given point in time. This is an important consideration in
terms of targeting the intervention to those patients who are most likely to be adherent and to
benefit in order to maximize physician time and resources and patient outcomes.
One strength of the current study is the degree to which the behavioral intervention was
viewed as acceptable and feasible by both patients and providers and could be easily adopted by
many primary care practices. It required no additional staff or resources and only minimal
training. By streamlining the behavioral weight loss counseling process through training and
materials to help guide individualized physician decision making, existing time and resources are
maximized. If obesity is more effectively managed with lifestyle modification in primary care,
many patients may not need medications, surgery, or referrals to specialty providers. Therefore,
they may avoid incurring extra costs and additional risk. A tiered model of care would reserve
the use of weight loss medications, specialized nutritional or exercise counseling, and bariatric
surgery for individuals who need more intensive care or are not responding to more basic
physician assisted interventions. This would also allow basic weight loss interventions to be
individualized and accessible to a larger portion of the population. Future research should
continue to support the development of a tiered model of care for obesity.
The widespread use of lifestyle modification as a first-tier treatment for obesity, with
additional interventions added as needed, is consistent with national treatment guidelines (Ryan,
2016) and has significant economic implications in addition to direct patient health benefits.
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Those who aren’t able to achieve significant weight loss or improvement in obesity-related
health conditions through brief behavioral intervention are at least gaining skills and knowledge.
For those patients who are successful in losing weight and/or reducing the severity of obesityrelated health conditions, there would likely be a reduction in the amount of money being spent
on medications and procedures for managing obesity and associated health conditions, thus
reducing overall medical spending. Additionally, if individuals are healthier, they will miss less
work and be less restricted in their activities, which will increase overall productivity. Having a
healthier population would decrease the demand on PCPs. If each individual patient required less
intensive care, then PCPs would be able to provide care to a larger population of individuals.
Indeed, previous research has found primary care behavioral interventions for obesity to be costeffective long-term (Tsai et al., 2013).
Limitations to the current study include the inconsistency of data collected across time
and participants, and also a lack of control over some extraneous variables, which may have
impacted the results. Standardization of time intervals and consistent physiological data
collection across participants were sacrificed in the current study in order to maximize time,
resource, and cost efficiency. Future studies should evaluate the feasibility and acceptability of
more intensive interventions that include standardization across time, participants, and measures,
and control over potentially confounding variables such as medication changes. Additionally,
the sample used in the current study was a recruited sample for research purposes, so it is unclear
whether or not the results are generalizable to a non-research patient population.
Another limitation of the current study is small sample size, which was largely the result
of abbreviated recruitment. It is also worth noting that, while the pool of eligible participants was
quite large among the patient population sampled, the number of eligible patients who ultimately
49

consented to participate was low (11%), even in comparison to other similar research studies. For
example, a systematic review of 17 studies in which researchers asked for access to data
contained in participant medical records revealed active consent rates ranging from 36.6% to
92.9% (Kho, Duffett, Willison, Cook, & Brouwers, 2009). In light of the low consent rate in the
current study, future research should consider alternative recruitment methods which might elicit
a higher response rate. Future studies should also attempt to replicate the current study with a
larger sample of participants, as a larger sample size would likely allow for the detection of more
consistent and robust effects.
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Western Michigan University
Department of Psychology and Homer Stryker School of Medicine
Principal Investigator:
Student Investigator:
Title of Study:

Wayne Fuqua, Ph.D.
Julia Huston, M.A.
Primary Care Physician Delivered Brief Behavioral Intervention
for Adult Obesity and Associated Health Conditions

You have been invited to participate in a research project titled “Primary Care Physician
Delivered Brief Behavioral Intervention for Adult Obesity and Associated Health Conditions”.
This project will serve as Julia Huston’s dissertation research project for the requirements of the
Doctoral degree. This consent document will explain the purpose of this research project and will
go over all of the time commitments, the procedures used in the study, and the risks and benefits
of participating in this research project. Please read this consent form carefully and completely
and please contact the researcher with any questions.
What are we trying to find out in this study?
Obesity is a chronic health condition with increasing prevalence rates worldwide. There are
many physical, mental, and economic costs associated with obesity and the many associated
health conditions that often accompany it. This study will evaluate the feasibility and
effectiveness of a brief, structured, lifestyle intervention for obesity and associated health
conditions delivered by primary care physicians.
Who can participate in this study?
You may participate if you are at least 18 years old, fluent in English, coming in for a chronic
health condition follow-up or yearly physical visit during the recruitment period, active on
Bronson MyChart, and have a BMI of at least 25. Women known to be pregnant will be
excluded from participating in the study due to the potential risks associated with weight loss
during pregnancy. If you become pregnant during the course of the study your participation will
be stopped immediately for your safety.
Where will this study take place?
The study will take place at Bronson Internal Medicine Oshtemo outpatient primary care office
within the context of your routine medical appointments.
What is the time commitment for participating in this study?
The time commitment for completing this study will involve spending about 10 minutes
completing questionnaires before regularly scheduled physician visits occurring over the course
of up to 12 months. Additionally, you may be asked to spend approximately 15 minutes per day
tracking your behavior at home and sending periodic MyChart updates to your physician.
What will you be asked to do if you choose to participate in this study?
If you choose to participate, you will be asked to complete a questionnaire about your current
exercise and eating habits, as well as measures assessing depression and sleep quality at
regularly scheduled physician visits occurring over a 12-month interval. Some of the questions
on these measures may cause you to feel upset. You may skip any questions that you do not wish
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to answer. It is possible that significant symptoms of depression may be identified through these
questionnaires. Your responses will be reviewed by your physician at each office visit and
appropriate follow-up care will be provided as needed. Additionally, you may be asked to
discuss weight, diet, and exercise with your physician during your regularly scheduled visits.
Finally, you may be asked to track your diet and exercise habits at home and send periodic
updates to your physician via MyChart.
What information is being measured during the study?
Physiological data collected during routine physician visits that occur during the data collection
period will be obtained from your EPIC medical record including:
 Weight
 BMI
 Blood pressure
 Cholesterol
 Hemoglobin A1c
Additionally, the following symptoms will be measured via self-report questionnaires which will
be completed via MyChart or in-person at all routine physician office visits that occur during the
data collection period:
 Sleep quality
 Depression
 Diet and exercise habits
Finally, treatment compliance and acceptability will be measured by:
 Frequency of physician-patient MyChart exchanges relevant to specific diet and exercise
goals created during office visits
 Consumer satisfaction questionnaires completed by patients and office staff
What are the risks of participating in this study and how will these risks be minimized?
One possible risk that you may experience is psychological distress produced by failure to lose
weight or follow through on exercise and diet goals. To minimize this risk, you will be offered
additional weight loss resources at the conclusion of the research study. Another potential risk is
the sharing of data collected during the research study. To minimize this risk all identifiable
participant data will be maintained at the Bronson Internal Medicine Office. Once collected, all
data will be de-identified and stored on a password protected external hard drive.
What are the benefits of participating in this study?
Direct benefits of the study may include weight loss, reduction in BMI and the severity of
obesity related health conditions, as well as improvements in mood and sleep quality.
Are there any costs associated with participating in this study?
Costs may include the effort necessary to modify daily habits and the time that it takes to
complete daily behavior tracking and report progress to physicians. To minimize this cost, goals
will be specific and realistic and tracking will be individualized.
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Is there any compensation for participating in this study?
There is no monetary compensation for participating in this study.
Who will have access to the information collected during this study?
Only the student investigator will have direct access to identifiable patient information collected
from questionnaires or the Bronson EPIC system. All Identifiable patient data will be maintained
at the Bronson Internal Medicine office. Both the primary and student investigators will have
access to de-identified participant data which will be maintained on a password-protected
external hard drive and stored in a locked cabinet in the WMU Behavioral Medicine Lab for at
least three years after the research study has ended. It is the intent of the researchers to present
this data at a professional conference and/or publish it in a journal article. At any point you may
choose to withdraw your permission for study investigators to access your previously collected
data. If you choose to do this, please contact either the primary (Wayne Fuqua) or student (Julia
Huston) investigators using the contact information provided below and your data will be
removed from all identifiable and de-identified data records associated with the research study.
What if you want to stop participating in this study?
Participation in this study is completely voluntary. There are no consequences for choosing not
to participate and your medical care will not be altered if you choose not to participate. If you
decide to participate, you can choose to withdraw from the study at any time for any reason.
You will not suffer any prejudice or penalty for choosing to stop your participation. You will
experience NO consequences if you choose not to participate or to withdraw from this study. If
you would like to withdraw from the study you may notify your physician in person or via
MyChart or the student investigator via MyChart at any time. The investigators can also decide
to stop your participation in the study without your consent.
Should you have any questions about your rights or any study procedures please contact the
primary investigator, Wayne Fuqua at 269-387-4474 or wayne.fuqua@wmich.edu or the student
investigator, Julia Huston at 740-603-2328 or julia.c.konkler@wmich.edu. Please let the study
investigators know immediately if you believe you have been injured in any way as a result of
your participation in the study. You may also contact the Chair of the WMU Human Subjects
Institutional Review Board at 269-387-8293 or the WMU Vice President for Research at 269387-8298 if questions or concerns about the research arise during the course of the study. You
may also contact the WMed Institutional Review Board by phone at 269-337-4345 or by e-mail
at wmedirb@med.wmich.edu.
This consent document has been approved for use for one year by both the WMU and WMed
Human Subjects Institutional Review Boards (HSIRB) as indicated by the stamped dates and
signatures of the board chairs in the upper right corner. Do not participate in this study if the
stamped date is older than one year.
------------------------------------------------------------------------------------------------------------------I have read this informed consent document. The risks and benefits have been explained to me. I
agree to take part in this study.
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Please type your full name below if you agree and send a message back containing a copy of the
complete document with your name typed below, or choose not to type your name below if you
do not agree and send a message back declining to participate. If you do not agree to participate,
you will experience no consequences for choosing not to participate.

Please Type Your Name
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Appendix B
Sleep Quality Questionnaire
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Sleep Quality Questionnaire
1. What time do you normally go to bed at night? What time do you normally wake up in the
morning?
2. Do you often have trouble falling asleep at night?

YES

NO

3. About how many times do you wake up at night?
4. If you do wake up during the night, do you usually have trouble falling back asleep?
YES

NO

5. Does your bed partner say (or are you aware) that you frequently snore, gasp for air or stop
breathing?

YES

NO

6. Does your bed partner say (or are you aware) you kick or thrash about while asleep?
YES

NO

7. Are you aware that you ever walk, eat, punch, kick, or scream during sleep?
YES

NO

8. Are you sleepy or tired during much of the day?

YES

NO

9. Do you usually take 1 or more naps during the day?

YES

NO

10. Do you usually doze off without planning to during the day?

YES

NO

11. How much sleep do you need to feel alert and function well?
12. Are you currently taking any type of medication or other preparation to help you sleep?
YES

NO
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Diet and Exercise Habits Questionnaire
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Diet and Exercise Habits Questionnaire
1. Please rank the following dietary changes in order of importance/relevance to you based
on changes that could reasonably be made to your current diet.
 Overall reduction in caloric intake (shoot for 1,600 calories daily to promote weight
loss but any reduction is better than no reduction)
 Reduction in fats consumed (increase fruits, vegetables, fiber, protein)
 Reduction in carbohydrates consumed (increase fruits, vegetables, fiber, protein)
 Reduction in sugars/sweets consumed (increase fruits, vegetables, fiber, protein)
 Reduction in portion sizes
 Eating several small, healthy meals/snacks throughout the day (every 2-3 hours)
rather than 2-3 large meals (this is especially helpful for people who are always on
the go or in the car for a large part of the day)
 Reduction in consuming fast food/eating out at restaurants
 Reduction in unhealthy snacking
 Increased water consumption
 Decreased consumption of sugary or alcoholic beverages (empty calories)

2. Please rank the following exercise changes in order of importance/relevance to you based
on changes that could reasonably be made to your current level of physical activity.
 Increase the frequency of exercise (more days/week)
 Increase the duration of current exercise efforts
 Increase the intensity of current exercise efforts (jogging instead of walking)`
 Include both strength and cardio in workouts (add in the missing component)
 Increase exercise during daily life activities (taking the stairs instead of the elevator,
lifting weights while watching TV, etc.)

3. On a scale from 1 (not motivated at all) to 10 (incredibly motivated) how motivated are
you to make the above changes to your diet/exercise habits?
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MyChart Recruitment Script

I am a clinical psychology doctoral student who has also been working as a Behavioral
Health Specialist at the Bronson Internal Medicine office. I am currently doing my
dissertation research project on obesity and its associated health conditions. I am recruiting
participants for a study that will examine the effectiveness and feasibility of a brief
behavioral intervention for obesity delivered by primary care physicians. If you are at least
18 years old, fluent in English, MyChart active, and have a BMI of 25+ you are eligible to
participate. Your participation would involve filling out brief questionnaires assessing your
diet and exercise habits, depression symptoms, and sleep quality. It would also involve the
collection of physiological data stored in your EPIC chart such as weight, BMI, blood
pressure, cholesterol, and hemoglobin A1c. Your participating may also involve setting diet
and exercise goals during regularly scheduled physician visits occurring over a 12 month
period, engaging in home behavior tracking, and sending periodic updates to your physician
via MyChart. I would greatly appreciate your help in gaining information about effective
treatment for obesity and its associated health conditions. Please reply to this message and
indicate whether or not you are interested in participating in this research project.
Thank you,
Julia Huston
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Physician Decision Guide
Diet modification strategies:
1. Overall reduction in caloric intake (shoot for 1,600 calories daily to promote weight loss
but any reduction is better than no reduction)
2. Reduction in fats consumed (increase fruits, vegetables, fiber, protein)
3. Reduction in carbohydrates consumed (increase fruits, vegetables, fiber, protein)
4. Reduction in sugars/sweets consumed (increase fruits, vegetables, fiber, protein)
5. Reduction in portion sizes
6. Eating several small, healthy meals/snacks throughout the day (every 2-3 hours) rather
than 2-3 large meals (this is especially helpful for people who are always on the go or in
the car for a large part of the day)
7. Reduction in consuming fast food/eating out at restaurants
8. Reduction in unhealthy snacking
9. Increased water consumption
10. Decreased consumption of sugary or alcoholic beverages (empty calories)
Exercise modification strategies:
1. Increase the frequency of exercise (more days/week)
2. Increase the duration of current exercise efforts
3. Increase the intensity of current exercise efforts (jogging instead of walking)`
4. Include both strength and cardio in workouts (add in the missing component)
5. Increase exercise during daily life activities (taking the stairs instead of the elevator,
lifting weights while watching TV, etc.)
Behavioral goal setting tips:
 Goals should be specific (what foods will be eaten and when, what types of exercises and
when will they occur)
 Goals should fit within daily routines (work within time and scheduling constraints)
 Goals should be accomplishable (for someone not exercising at all, the next step might be
walking once/week)
 Patients should be encouraged to reward themselves for meeting goals (rewards can be
small, inexpensive, and frequent or larger and more infrequent)
 Patient should be encouraged to engage in daily behavior tracking to monitor progress
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Participant Information Sheet
As a part of your participation in the current research project, you will be receiving a brief
behavioral weight loss intervention delivered by your primary care physician. As a part of this
intervention, you will be asked to complete a few tasks.
1. Please use some form of at home tracking to monitor your daily food intake and physical
activity as appropriate according to your specific diet and exercise goals. Below is a link
to one possible type of tracking sheet that you may find helpful. Depending on your
specific goals, all parts of this form may not be relevant. Please utilize the pieces that are
relevant or find a different tracking form or electronic app (my fitness pal, etc.) that you
find more helpful. (http://www.webmd.com/diet/printable/food-fitness-journal).
2. Once every week/two weeks/month (depending on the stage of the study) you will be
prompted to send a MyChart message to your physician briefly summarizing:
 Progress towards the specific diet and exercise goals established collaboratively
with your physician during your office visit (utilize the information from your
tracking forms/app to assist you in monitoring your progress towards your goals).
 Any areas where you are struggling to reach your goals.
 Current weight (it is important to weight yourself at approximately the same time
each day wearing approximately the same clothing).
Your physician will provide you with feedback on your progress via MyChart.
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Consumer Satisfaction Questionnaire
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Consumer Satisfaction Questionnaire
Please answer the following questions on a scale from 1 (strongly disagree) to 5 (strongly agree).
The word intervention refers to specific behavioral goal setting during office visits plus regular
between visit MyChart check-ins.
1. I found this intervention to be helpful/valuable.

2. I found the time required to participate in this intervention reasonable and manageable.

3. I would recommend this intervention to others.

Please provide any additional comments that you may have about the intervention below.
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Appendix H
Western Michigan University Human Subjects Institutional
Review Board Letter of Approval
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Appendix I
Homer Stryker School of Medicine/Bronson Hospital Human Subjects
Institutional Review Board Letter of Approval
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